Home / Pharmaceutical / Global Cutaneous Mastocytosis Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026

Global Cutaneous Mastocytosis Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026

Published: Apr 2019 | Published By: Acute Market Research

The global cutaneous mastocytosis treatment market was valued at USD 186.7 Mn in 2017, and is expected to reach USD 302.2 Mn by 2026, expanding at a CAGR of 5.6% from 2018 to 2026.

Market Insights:

Cutaneous mastocytosis a genetic disorder that primarily targets skin and there are three types of conditions such as solitary cutaneous mastocytoma, maculopapular cutaneous mastocytosis (urticaria pigmentosa) and diffuse cutaneous mastocytosis. Urticaria pigmentosa is usually found in adults and rarely in young children, while solitary cutaneous mastocytoma is typically diagnosed in young children. There is another type of cutaneous mastocytosis which is considered as its rarest form called telangiectasia macularis eruptiva perstans. Thus, cutaneous mastocytosis is an orphan disease due to which its prevalence in general population is recorded only in developed & a few developing countries globally. According to Orphanet, the prevalence of cutaneous mastocytosis is unknown in the general population but this condition is expected to fall in a range of 0.1 to 0.8% of all dermatological conditions diagnosis. It has been also observed that cutaneous mastocytosis is commonly found in the Caucasian population.
Antihistamines were observed as the largest segment in cutaneous mastocytosis treatment market in year 2017 as histamines are considered as first line of defense to give symptomatic relief associated with formation of lesions & blisters on skin surface and primarily reduce itching. Histamine-2 (H2) blockers also assist in relieving digestive upset.

North America was observed as the largest cutaneous mastocytosis market globally in 2017 and will maintain its dominance throughout the forecast period from 2018 to 2026. The key factors responsible for its market dominance are rising prevalence of cutaneous mastocytosis coupled with high awareness related to the disease in medical practitioners, and availability of novel diagnosis and treatment facilities.

Market Competition Assessment:

The cutaneous mastocytosis treatment market is growing gradually and awareness related to the disease is growing significantly. However, the pipeline is weak and major companies operating in this market lacks in innovation and ground-breaking treatment. The key companies present in the global cutaneous mastocytosis treatment market are Novartis AG, Mylan NV, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., Johnson & Johnson, Bayer AG, and Mallinckrodt Pharmaceuticals among others.

Key Market Movements:

• Increasing prevalence and awareness related to cutaneous mastocytosis treatment & diagnosis expected to assist the market growth
• Incessant demand for development of target-specific treatment for cutaneous mastocytosis treatment
• Rising diagnosis rate related to developed and developing countries will increase the need for effective cutaneous mastocytosis treatment market
• The pipeline drugs Mastinib & TF 002 are expected to assist the growth of the overall market in the near future
• Being an orphan disease and complexities related to diagnosis and disease management initiative related to research & development activities are expected to aid the future market growth

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Cutaneous Mastocytosis Treatment Market Portraiture
2.2. Global Cutaneous Mastocytosis Treatment Market, by Type of Drug Class, 2017 (US$ Mn)
2.3. Global Cutaneous Mastocytosis Treatment Market, by Geography, 2017 Vs 2026 (Value %)

Chapter 3. Global Cutaneous Mastocytosis Treatment Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2017

Chapter 4. Global Cutaneous Mastocytosis Treatment Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Antihistamines
4.3. Corticosteroids
4.4. Mast Cell Stabilizers
4.5. Sympathomimetic Agents (Ephinephrine)
4.6. Photochemotherapy

Chapter 5. Global Cutaneous Mastocytosis Treatment Market: Pipeline Analysis
5.1. Overview
5.2. Phase III [Till 2026] (U$ Mn)
5.2.1. Mastinib
5.3. Phase II (Qualitative Information)
5.3.1. TF 002

Chapter 6. Global Cutaneous Mastocytosis Treatment Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. Overview
6.2. North America Cutaneous Mastocytosis Treatment Market Analysis, 2016 – 2026
6.2.1. North America Cutaneous Mastocytosis Treatment Market, by Type of Drug Class, 2016–2026 (US$ Mn)
6.2.2. North America Cutaneous Mastocytosis Treatment Market, by Country, 2016 – 2026 (US$ Mn)
6.2.2.1. U.S.
6.2.2.2. Canada
6.3. Europe Cutaneous Mastocytosis Treatment Market Analysis, 2016 – 2026
6.3.1. Europe Cutaneous Mastocytosis Treatment Market, by Type of Drug Class, 2016–2026 (US$ Mn)
6.3.2. Europe Cutaneous Mastocytosis Treatment Market, by Country, 2016 – 2026 (US$ Mn)
6.3.2.1. U.K.
6.3.2.2. Germany
6.3.2.3. Rest of Europe
6.4. Asia Pacific Cutaneous Mastocytosis Treatment Market Analysis, 2016 – 2026
6.4.1. Asia Pacific Cutaneous Mastocytosis Treatment Market, by Type of Drug Class, 2016–2026 (US$ Mn)
6.4.2. Asia Pacific Cutaneous Mastocytosis Treatment Market, by Country, 2016 – 2026 (US$ Mn)
6.4.2.1. Japan
6.4.2.2. China
6.4.2.3. Rest of APAC
6.5. Latin America Cutaneous Mastocytosis Treatment Market Analysis, 2016 – 2026
6.5.1. Latin America Cutaneous Mastocytosis Treatment Market, by Type of Drug Class, 2016–2026 (US$ Mn)
6.5.2. Latin America Cutaneous Mastocytosis Treatment Market, by Country, 2016 – 2026 (US$ Mn)
6.5.2.1. Brazil
6.5.2.2. Mexico
6.5.2.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Cutaneous Mastocytosis Treatment Market Analysis, 2016 – 2026
6.6.1. Middle East & Africa Cutaneous Mastocytosis Treatment Market, by Type of Drug Class, 2016–2026 (US$ Mn)
6.6.2. MEA Cutaneous Mastocytosis Treatment Market, by Region, 2016 – 2026 (US$ Mn)
6.6.2.1. GCC
6.6.2.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Pfizer Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Merck & Co., Inc.
7.3. EPI Health, LLC.
7.4. kaleo, Inc.
7.5. Bausch Health Companies Inc.
7.6. Mylan N.V.
7.7. Sanofi
7.8. Mallinckrodt
7.9. Bayer AG
7.10. Teva Pharmaceutical Industries Ltd.
7.11. Novartis AG
7.12. Johnson & Johnson

TABLE 1 : Global Cutaneous Mastocytosis Treatment Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
TABLE 2 : North America Cutaneous Mastocytosis Treatment Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
TABLE 3 : North America Cutaneous Mastocytosis Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 4 : Europe Cutaneous Mastocytosis Treatment Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
TABLE 5 : Europe Cutaneous Mastocytosis Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 6 : Asia Pacific Cutaneous Mastocytosis Treatment Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
TABLE 7 : Asia Pacific Cutaneous Mastocytosis Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 8 : Latin America Cutaneous Mastocytosis Treatment Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
TABLE 9 : Latin America Cutaneous Mastocytosis Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 10 : Middle East & Africa Cutaneous Mastocytosis Treatment Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
TABLE 11 : Middle East And Africa Cutaneous Mastocytosis Treatment Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 12 : Pfizer Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 13 : Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 14 : EPI Health, LLC.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 : kaleo, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 : Bausch Health Companies Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 : Mylan N.V.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 : Sanofi: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 : Mallinckrodt: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 : Bayer AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 : Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 : Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 : Johnson & Johnson: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)

FIG. 1 : Cutaneous Mastocytosis Treatment: Market Segmentation
FIG. 2 : Global Cutaneous Mastocytosis Treatment Market, by Type of Drug Class, 2017 (US$ Mn)
FIG. 3 : Global Cutaneous Mastocytosis Treatment Market, by Geography, 2017 Vs 2026 (US$ Mn)
FIG. 4 : Attractive Investment Proposition, by Geography, 2017
FIG. 5 : Market Competition Landscape, by Key Players, 2017
FIG. 6 : Global Antihistamines Market for Cutaneous Mastocytosis Treatment, 2016 – 2026 (US$ Mn)
FIG. 7 : Global Corticosteroids Market for Cutaneous Mastocytosis Treatment, 2016 – 2026 (US$ Mn)
FIG. 8 : Global Mast Cell Stabilizers Market for Cutaneous Mastocytosis Treatment, 2016 – 2026 (US$ Mn)
FIG. 9 : Global Sympathomimetic Agents Market for Cutaneous Mastocytosis Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 10 : Global Photochemotherapy Market for Cutaneous Mastocytosis Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 11 : Global Mastinib Market for Cutaneous Mastocytosis Treatment, Till 2026 (US$ Mn)
FIG. 12 : U.S. Cutaneous Mastocytosis Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 13 : Canada Cutaneous Mastocytosis Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 14 : U.K. Cutaneous Mastocytosis Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 15 : Germany Cutaneous Mastocytosis Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 16 : Rest Of Europe Cutaneous Mastocytosis Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 17 : Japan Cutaneous Mastocytosis Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 18 : China Cutaneous Mastocytosis Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 19 : Rest Of Asia Pacific Cutaneous Mastocytosis Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 20 : Brazil Cutaneous Mastocytosis Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 21 : Mexico Cutaneous Mastocytosis Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 22 : Rest Of Latin America Cutaneous Mastocytosis Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 23 : GCC Cutaneous Mastocytosis Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 24 : Rest Of Middle East And Africa Cutaneous Mastocytosis Treatment Market, 2016 – 2026 (US$ Mn)

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +